{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:55:01Z","timestamp":1792896901710,"version":"4.5.0"},"reference-count":45,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009406","name":"Centre Hospitalier Universitaire de Nantes","doi-asserted-by":"publisher","award":["AOI 2017"],"award-info":[{"award-number":["AOI 2017"]}],"id":[{"id":"10.13039\/501100009406","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical &amp; Translational Med"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Post\u2010transplant cyclophosphamide (PTCY) alone as graft\u2010versus\u2010host disease (GVHD) prophylaxis may avoid\/reduce short\u2010 and mid\u2010term toxicities of drugs commonly used for GVHD prophylaxis, accelerate immune reconstitution after the graft to decrease infections and facilitate the early integration of adjunct maintenance therapies to prevent relapse.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>A prospective phase 2 study was designed in order to assess the feasibility and safety of PTCY as a sole GVHD prophylaxis in adult patients receiving a Baltimore\u2010based reduced\u2010intensity conditioning (RIC) peripheral blood (PB) allogeneic hematopoietic stem cell transplantation (Allo\u2010HSCT) with a matched donor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study design<\/jats:title><jats:p>Patients were planned to be included stepwise up to 59 evaluable PTCY recipients, in order to be able to stop the protocol in case of excessive corticosteroid resistant grade 3\u20134 severe acute GVHD (aGVHD). Because a high incidence of grade 2\u20134 aGVHD was observed after analysis of the first 27 patients, the protocol was amended to test the addition of 1 day of anti\u2010thymoglobulin to PTCY. In spite of this, the trial had to be stopped after 38 treated patients, because of an unacceptable rate of grade 3\u20134 aGVHD. Donors were matched related to 12 patients and unrelated to 26.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>With a median follow\u2010up of 29.6 months, 2\u2010year overall, disease\u2010free and GVHD\u2010free relapse\u2010free (GRFS) survivals were respectively 65.4%, 62.1% and 46.9%. Cumulative incidences of grade 2\u20134 and 3\u20134 aGVHD at day 100 were 52.6% and 21.1%, respectively, while that of moderate\/severe chronic(c) GVHD was 15.7% at 2 years. Addition of ATG to PTCY did influence neither aGVHD, cGVHD nor GRFS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Despite paradoxically good survivals, especially GRFS, this study failed to demonstrate that PTCY (\u00b1\u00a0ATG) alone can be used for Baltimore\u2010based RIC PB Allo\u2010HSCT with matched donors. Other combinations should be tested to try and avoid long\u2010term use of immunosuppressive drugs following Allo\u2010HSCT in this setting.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ctm2.1242","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T10:55:41Z","timestamp":1682506541000},"source":"Crossref","is-referenced-by-count":4,"title":["Post\u2010transplant cyclophosphamide as sole GHVD prophylaxis after matched reduced\u2010intensity conditioning allotransplant"],"prefix":"10.1002","volume":"13","author":[{"given":"Amandine Le","family":"Bourgeois","sequence":"first","affiliation":[{"name":"Hematology Department Nantes University Hospital  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Jullien","sequence":"additional","affiliation":[{"name":"Hematology Department Nantes University Hospital  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Garnier","sequence":"additional","affiliation":[{"name":"Hematology Department Nantes University Hospital  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Peterlin","sequence":"additional","affiliation":[{"name":"Hematology Department Nantes University Hospital  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie C.","family":"B\u00e9n\u00e9","sequence":"additional","affiliation":[{"name":"INSERM UMR1232 CRCINA IRS\u2010UN University of Nantes  Nantes France"},{"name":"Hematology Biology Nantes University Hospital  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Guillaume","sequence":"additional","affiliation":[{"name":"Hematology Department Nantes University Hospital  Nantes France"},{"name":"INSERM UMR1232 CRCINA IRS\u2010UN University of Nantes  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3142-5581","authenticated-orcid":false,"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[{"name":"Hematology Department Nantes University Hospital  Nantes France"},{"name":"INSERM UMR1232 CRCINA IRS\u2010UN University of Nantes  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00636"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185\u2010022\u201003428\u20103"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30221-7"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00923-0"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33255"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04317-7"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005847"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.11.013"},{"issue":"22","key":"e_1_2_7_10_1","first-page":"01476","article-title":"Characteristics of graft\u2010versus\u2010host disease (GvHD) after post\u2010transplant cyclophosphamide versus conventional GvHD prophylaxis","volume":"2666","author":"Saliba RM","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"e_1_2_7_11_1","unstructured":"BrissotE LapobinM LabussiereH et al.Post\u2010transplantation cyclophosphamide versus anti\u2010thymocyte globulin after RIC regimen allo\u2010HCT: first analysis of a prospective randomized multicenter trial in recipients of 10\/10 matched donors.Presidential Symposium #GS2\u20102. 47th Annual Meeting of the EBMT; Mar 15 2021; Virtual."},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-251595"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-587477"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.0625"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.767"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02293"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.08.034"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.10.034"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.01.026"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12541"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.01.020"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05614.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.03.005"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26083"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.09.001"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.12.001"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.7.2426"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007336"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1541-0420.2005.00311.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703360"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-609032"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.305"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.03.004"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000236"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10061173"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0586-4"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.02.008"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.05.024"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.07.020"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-017-0053-9"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13230"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11041106"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.09.032"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0183-8"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.07.023"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.07.021"}],"container-title":["Clinical and Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ctm2.1242","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T21:23:39Z","timestamp":1692653019000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ctm2.1242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1002\/ctm2.1242"],"URL":"https:\/\/doi.org\/10.1002\/ctm2.1242","archive":["Portico"],"relation":{},"ISSN":["2001-1326","2001-1326"],"issn-type":[{"value":"2001-1326","type":"print"},{"value":"2001-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]},"article-number":"e1242"}}